Biology & biomedicineA more effective nanomedicine has been developed for the treatment of Fabry rare disease
- Details
- Category: Success stories
-
26 Feb 2021
This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work. The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future. The new drug improves on current treatments and helps reduce costs and improve patients' quality of life.
SINGEK trains a new generation of Single Cell Genomics experts
- Details
- Category: Projects
-
13 Jan 2021
The SINGEK project is now finished. It was a project coordinated by the Institut de Ciències del Mar (ICM, by its Spanish acronym) of the CSIC, and it had as a main goal the training of young researchers in the application of single cell genomics for the study of microbial eukaryotes’ ecology and evolution. This emerging methodology also has applications in biotechnology and biomedicine.
Antibodies test for Covid-19 with near 100% accuracy
- Details
- Category: Success stories
-
29 Dec 2020
A new serological test for Covid-19 with an accuracy close to 100% has been developed by researchers from the CSIC, in collaboration with the hospitals of La Princesa and La Paz. The Spanish biotechnology company Immunostep produces and commercializes the test.
A laboratory at the IQAC-CSIC obtains the biosafety level 2 accreditation
- Details
- Category: Laboratories
-
29 Dec 2020
The Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) has obtained the biosafety level 2 accreditation for one of its laboratories, which allows the laboratory to work with biological agents classified in the risk group 2.
A new therapeutic target for the treatment of nonalcoholic fatty liver disease
- Details
- Category: Projects
-
25 Nov 2020
Scientists of the IIBB-CSIC discover a new role for sphingomyelin synthase 1 enzyme in nonalcoholic steatohepatitis, an advanced stage of fatty liver disease. The work identifies SMS1 enzyme as a possible new therapeutic target.
